Tag: M.W:200-300

111769-27-8, Catalysts function by providing an alternate reaction mechanism that has a lower activation energy than would be found in the absence of the catalyst. In some cases, the catalyzed mechanism may include additional steps.In a article, 111769-27-8, molcular formula is C11H17NO4S, introducing its new discovery.

TRIAZOLOPYRIDINE COMPOUNDS

The invention is concerned with triazolopyridine compounds of formula (I) wherein R1, R2, R3 and R4 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit PDE10A and can be used as pharmaceuticals.

Because enzymes can increase reaction rates by enormous factors and tend to be very specific, 111769-27-8, typically producing only a single product in quantitative yield, they are the focus of active research.you can also check out more blogs about 111769-27-8

Reference£º
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

104227-71-6, Chemistry is the experimental and theoretical study of materials on their properties at both the macroscopic and microscopic levels.In a patent£¬Which mentioned a new discovery about 104227-71-6

Diamine derivatives

A compound represented by the general formula (1): Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4??(1) wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group 1 in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger’s disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

104227-71-6, Each elementary reaction can be described in terms of its molecularity, the number of molecules that collide in that step. The slowest step in a reaction mechanism is the rate-determining step.you can also check out more blogs about 104227-71-6!

Reference£º
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

118399-28-3, Chemistry is the experimental and theoretical study of materials on their properties at both the macroscopic and microscopic levels.In a patent£¬Which mentioned a new discovery about 118399-28-3

Chiral quinolone intermediates

Chiral compounds having the formulae STR1 useful in the synthesis of quinolone intermediates.

118399-28-3, If you are hungry for even more, make sure to check my other article about 118399-28-3

Reference£º
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

219823-47-9, Chemistry is the experimental and theoretical study of materials on their properties at both the macroscopic and microscopic levels.In a patent£¬Which mentioned a new discovery about 219823-47-9

according to handkerchief row only crystal form and its preparation method, pharmaceutical composition and use thereof (by machine translation)

The present invention relates to new crystalline forms of purifying according to handkerchief row, the new crystal compared with the known crystal form has a plurality of improved characteristics, is suitable for the application of pharmaceutical preparation. The invention also relates to novel crystal forms of the preparation method, the medicament composition and its use in treating and/or preventing diabetes mellitus type II use of the medicament. (by machine translation)

219823-47-9, Interested yet? Read on for other articles about 219823-47-9!

Reference£º
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

118399-28-3, (R)-Benzyl (5-oxotetrahydrofuran-3-yl)carbamate is a Tetrahydrofurans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

16. Synthesis of intermediate 5d (0404) Exact Mass: 418.26 (0405) (0406) 4 (0407) [00139] To the solution of intermediate 4 (6.5 g, 27.7 mmol) in THF (60 mL) was added d (5.0 g, 27.7 mmol), and the solution was stirred at room temperature overnight. After completion of the reaction, the solvent was removed in vacuo, the residue was purified by chromatography column (PE/EA = 1/1) to afford intermediate 5d (7.6 g, 66%) as yellow oil. MS (M+H)+ 419.4 7., 118399-28-3

118399-28-3 (R)-Benzyl (5-oxotetrahydrofuran-3-yl)carbamate 697924, aTetrahydrofurans compound, is more and more widely used in various fields.

Reference£º
Patent; MERRIMACK PHARMACEUTICALS, INC.; DRUMMOND, Daryl, C.; GENG, Bolin; KIRPOTIN, Dmitri, B.; TIPPARAJU, Suresh, K.; KOSHKARYEV, Alexander; (125 pag.)WO2017/123616; (2017); A1;,
Tetrahydrofuran – Wikipedia
Tetrahydrofuran | (CH2)3CH2O – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.104227-71-6,(S)-tert-Butyl (5-oxotetrahydrofuran-3-yl)carbamate,as a common compound, the synthetic route is as follows.

REFERENTIAL EXAMPLE 195 tert-Butyl (3S,4S)-4-azido-5-oxotetrahydro-3-furanylcarbamate: 1 M Lithium bis(trimethylsilyl)amide (tetrahydrofuran solution, 8.65 ml) was added dropwise to a solution of the compound (0.87 g) obtained in Referential Example 194 in tetrahydrofuran (20 ml) at -78 C., and the mixture was stirred for 30 minutes. After a solution of p-toluenesulfonylazide (1.02 g) in tetrahydrofuran (10 ml) was then added, and the mixture was stirred for 5 minutes, trimethylchlorosilane (1.7 ml) was added, and the mixture was stirred for 2 hours while the temperature of the system was gradually raised to room temperature. The reaction mixture was diluted with diethyl ether, washed with 10% hydrochloric acid, a 5% saturated aqueous solution of sodium hydrogencarbonate and saturated aqueous solution of sodium chloride, and then dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure. The resultant residue was purified by column chromatagraphy on silica gel (hexane:ethyl acetate=4:1) to obtain the title compound (0.62 g). 1H-NMR (CDCl3) delta: 1.46(9H,s), 4.09(1H,dt,J=15.3, 7.6 Hz), 4.12-4.23(1H,m), 4.37-4.50(1H,m), 4.54(1H,dd,J=9.0, 7.6 Hz), 4.81-4.90(1H,m)

104227-71-6, As the paragraph descriping shows that 104227-71-6 is playing an increasingly important role.

Reference£º
Patent; DAIICHI PHARMACEUTICAL CO., LTD.; US2005/20645; (2005); A1;,
Tetrahydrofuran – Wikipedia
Tetrahydrofuran | (CH2)3CH2O – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.111769-27-8,(R)-Tetrahydrofuran-3-amine 4-methylbenzenesulfonate,as a common compound, the synthetic route is as follows.

To a solution of (2,6-dimethylpyridin-4-yl)methyl 4-nitrophenyl carbonate (Intermediate 2;235 mg, 0.78 mmol) in DMF (5 mL) was added DIPEA (400 muL, 2.3 mmol), (R)- tetrahydrofuran-3 -amine toluenesulfonate (221 mg, 0.85 mmol) and DMAP (10 mg, catalytic). The reaction mixture was stirred overnight and then concentrated in vacuo. The residue was dissolved in EtOAc (25 mL), washed with IM aq Na2CO3 solution (5 x 25 mL), dried (MgSO4) and concentrated in vacuo. The residue was dissolved in DCM (5 mL) and treated with 2M HCl in Et2O (0.5 mL, 1.0 mmol) to give a precipitate. The – -solvent was removed by decantation and the precipitate was dried in vacuo to give (2,6- dimethylpyridin-4-yl)methyl (3R)-tetrahydrofuran-3-ylcarbamate hydrochloride (102 mg, 46%) as a white solid.Analytical HPLC: purity 99.3% (System A, Rtau = 3.03 min); Analytical LCMS: purity 100% (System E, Rtau = 4.59 min), ES+: 251.4 [MH]+; HRMS calcd for Ci3Hi8N2O3: 250.1317, found 250.1330.

111769-27-8, The synthetic route of 111769-27-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; BIOVITRUM AB (PUBL); WO2009/147216; (2009); A1;,
Tetrahydrofuran – Wikipedia
Tetrahydrofuran | (CH2)3CH2O – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.111769-27-8,(R)-Tetrahydrofuran-3-amine 4-methylbenzenesulfonate,as a common compound, the synthetic route is as follows.

Example 294-((R)-2-{[6-phenyl-(R)-4-(tetrahydro-furan-3-ylamino)-pyridine-2-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester29.1. 4-{3-(ethoxy-hydroxy-phosphoryl)-2-[(6-phenyl-4-pyrrolidin-1-yl-pyridine-2-carbonyl)-amino]-propionyl}-piperazine-1-carboxylic acid butyl esterA reaction mixture containing intermediate 25.1 (100 mg), (R)-(+)-3-aminotetrahydrofurane to luene-4-sulfonate (43 mg), acetato (2′-di-tert-butylphosphino-1,1′-biphenyl-2-yl)palladium (9.7 mg) and NaOtBu (46 mg) in toluene (1 mL) at 90 C. under argon until reaction completion. The solvent was evaporated in vacuo and the crude product (119 mg) used without further purification.LC-MS: tR=0.78 min; [M+H]+: 632.16., 111769-27-8

111769-27-8 (R)-Tetrahydrofuran-3-amine 4-methylbenzenesulfonate 14243169, aTetrahydrofurans compound, is more and more widely used in various fields.

Reference£º
Patent; Caroff, Eva; Hilpert, Kurt; Hubler, Francis; Meyer, Emmanuel; Renneberg, Dorte; US2011/46089; (2011); A1;,
Tetrahydrofuran – Wikipedia
Tetrahydrofuran | (CH2)3CH2O – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.219823-47-9,(R)-Tetrahydrofuran-3-yl 4-methylbenzenesulfonate,as a common compound, the synthetic route is as follows.

At room temperature, 3-methoxy-4-bromophenol (0.4 g, 1.97 mmol) and cesium carbonate (0.96 g, 2.96 mmol) were added to a solution of compound 15-c (0.43 g, 1.78 mmol) in N,N-dimethylformamide (4 mL) respectively. After the addition, the reaction solution was stirred at 80 C. for 16 hours. The reaction solution was diluted with ethyl acetate (10 mL), washed sequentially with water (10 mL¡Á3) and brine (10 mL¡Á3). The organic phase was dried over anhydrous sodium sulfate and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether: ethyl acetate=10:1) to give compound 15-b (0.31 mg, yield 64%). (0265) 1H-NMR (400 MHz, CDCl3) delta: 7.40 (d, J=8.4 Hz, 1H), 6.48 (d, J=2.8 Hz, 1H), 6.33 (dd, J=2.8, 8.8 Hz, 1H), 4.85-4.94 (m, 1H), 3.94-4.05 (m, 3H), 3.87-3.94 (m, 1H), 3.86 (s, 3H), 2.07-2.29 (m, 2H) ppm

219823-47-9, The synthetic route of 219823-47-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD.; XU, Zusheng; ZHANG, Nong; WANG, Tinghan; SUN, Qingrui; WANG, Yuguang; (90 pag.)US2018/208604; (2018); A1;,
Tetrahydrofuran – Wikipedia
Tetrahydrofuran | (CH2)3CH2O – PubChem

104227-71-6, (S)-tert-Butyl (5-oxotetrahydrofuran-3-yl)carbamate is a Tetrahydrofurans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

4-Bromoaniline (172 mg) was dissolved in dichloromethane (5 ml). To the solution, trimethylaluminum (1.8 M solution in toluene, 0.556 ml) was added, and the mixture was stirred at room temperature for 15 minutes. Tert-butyl N-[(3S)-5-oxotetrahydrofuran-3-yl]carbamate (201 mg) was added to the reaction solution, and the mixture was stirred overnight at room temperature, then stirred at 60 C. for 1 hour, and then further heated to reflux for 1 hour. (0416) The same procedures as above were performed using 4-bromoaniline (2.56 g), and two lots were combined. Water was added to the reaction solution, followed by extraction from the aqueous layer with ethyl acetate. The aqueous layer was filtered through celite. After extraction from the filtrate with dichloromethane, these two organic layers were combined, dried over anhydrous sodium sulfate and then concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (n-hexane-ethyl acetate) to obtain the title compound (3.82 g). (0417) 1H-NMR (DMSO-d6) delta: 1.34 (9H, s), 2.39 (1H, dd, J=14.9, 7.4 Hz), 2.54 (1H, dd, J=14.9, 5.7 Hz), 3.28-3.35 (1H, m), 3.36-3.41 (1H, m), 3.82-3.88 (1H, m), 4.70-4.78 (1H, m), 6.59 (1H, d, J=8.6 Hz), 7.45-7.48 (2H, m), 7.54-7.57 (2H, m), 9.97 (1H, s). (0418) ESI-MS (m/z): 373, 375 (M+H)+.

104227-71-6, 104227-71-6 (S)-tert-Butyl (5-oxotetrahydrofuran-3-yl)carbamate 10943528, aTetrahydrofurans compound, is more and more widely used in various fields.

Reference£º
Patent; Daiichi Sankyo Company, Limited; Takeda, Yasuyuki; Yoshikawa, Kenji; Kagoshima, Yoshiko; Yamamoto, Yuko; Tanaka, Ryoichi; Tominaga, Yuichi; Kiga, Masaki; Hamada, Yoshito; (132 pag.)US2016/46639; (2016); A1;,
Tetrahydrofuran – Wikipedia
Tetrahydrofuran | (CH2)3CH2O – PubChem